Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2022 07:00 ET | Source: Kamada Ltd.

Kamada to Host a Virtual Analysts and Investors Meeting to Review its Growth Catalysts

REHOVOT, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics,...
May 17, 2022 07:05 ET | Source: Kamada Ltd.

Kamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022

First Quarter 2022 Revenues were $28.1 Million, Up 13% Year Over Year.Kamada Reiterates Fiscal Year 2022 Revenue Guidance of $125 - $135 Million, Representing a 20% to 30% Increase over 2021 and...
May 17, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification

REHOVOT, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived...
May 11, 2022 07:00 ET | Source: Kamada Ltd.

Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022

REHOVOT, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics,...
March 15, 2022 07:05 ET | Source: Kamada Ltd.

Kamada Issues 2022 CEO Letter to Shareholders

REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived...
March 15, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022

Total Revenues for Fiscal Year 2021 were $103.6 Million and Fourth Quarter 2021 Revenues were $31.5 Million. Fiscal Year 2022 Revenues are Expected to Range Between $125 Million to $135 Million,...
March 14, 2022 08:00 ET | Source: Kamada Ltd.

Kamada Expands U.S. Leadership Team with Two Key Appointments

REHOVOT, Israel, March 14, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived...
March 02, 2022 07:00 ET | Source: Kamada Ltd.

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022

REHOVOT, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
November 22, 2021 07:05 ET | Source: Kamada Ltd.

Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products

2021 Global Revenue of the Portfolio Acquired from Saol Therapeutics is Estimated Between $40 Million to $45 Million, with Approximately 75% and 20% of Sales Generated from U.S. and Canada,...
November 22, 2021 07:00 ET | Source: Kamada Ltd.

Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products

Third Quarter 2021 Revenues were $23.0 Million and Total Revenues for the First Nine Months of 2021 were $72.2 MillionKamada has Acquired a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune...